AndhraNews.net
Home » Business News » 2011 » March » March 16, 2011

Mellow Hope (HTDS) Increases Indian Vaccine Sales


March 16, 2011 - Shenzhen, China

Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced that its China-based Shenzhen Mellow Hope subsidiary had a major leap in sales volume for its Hepatitis A (MEVAC-A) vaccine in India in 2010 compared to a year earlier.

Mellow Hope launched the Hepatitis A vaccine in India at the end of 2005, and its high quality and competitive pricing has enabled it to steadily increase its market share year by year. MEVAC-A has been embraced by Indian doctors and patients in need of the vaccine, which has given Mellow Hope a very good reputation in the country.

Mellow Hope believes that it can capitalize on the success and wide acceptance of MEVAC-A and create more business opportunities in India, which should increase profits for HTDS and add value for shareholders.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contacts:
For medical and scientific dialogue inquiry only,
please contact
medicalinfo@htdsmedical.com

MarketWire

Comment on this story

Share